Elision International Inc. ELIS 深 沪
等待开盘 12-18 09:30:00 美东时间
18.4139
+0.256
+1.41%
华盛通- 最 高18.469
- 今 开18.279
- 成交量 1840股
- 最 低 18.0971
- 昨 收 18.1578
- 总市值 230.17万
- 52周最高 31.1325
- 市盈率 静 --
- 换手率 1.47%
- 52周最低 17.25
- 委 比 0.00%
- 总股本 12.50万
- 历史最高 31.1325
- 量 比 0.09
- 振 幅 2.05%
- 历史最低 17.25
- 每 手 1
- 风险率 3.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alnylam Pharma To Invest $250M To Advance siRNA Enzymatic-Ligation Manufacturing Facility
New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipelineFDA has accepted Alnylam's enzymatic ligation manufacturing platform into its
12-17 21:03
Axcelis to Showcase Advanced Ion Implant Solutions at SEMICON Japan 2025
BEVERLY, Mass., Dec. 10, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced t...
12-10 21:00
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs
As the largest publicly traded U.S. healthcare enterprise, Eli Lilly & Co. ...
10-13 22:10
Immuron Advances FDA Filings And Preps 2025 Launch Of New IBS Treatment ProIBS, Eyes October Results For Travelan US Military Trial
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders with a brief update on progress with a number of projects.SalesAs
10-02 18:08
加速生命科学大模型落地，腾讯构建了一个新的AI生态
众多投身生命科学的互联网公司中，腾讯或是最先破局的那一个。 2025年的腾讯全球数字生态大会中，腾讯健康总裁吴文达对腾讯的生命科学解决方案进行了一次全方位的拆解...
09-22 08:04
泰格医药子公司方达控股5月双捷报：苏州与上海实验室均以“零缺陷”通过FDA核查
2025年5月，方达控股旗下苏州生物分析实验室和上海生物分析实验室相继接受了美国食品药品监督管理局（FDA）的现场核查，均以“零缺陷”顺利通过，充分展现了方达控...
05-22 09:13
AbbVie Cancer Drug Approval Fails to Lift ABBV Stock
AbbVie stock fell alongside an analyst downgrade despite the company receiving ...
05-15 20:24
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.
05-15 03:25
